Loading
Serabelisib is an experimental small-molecule drug from Faeth Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer and endometrial cancer, aimed at PIK3CA / PI3K-alpha.
Serabelisib (FTH-001, MLN1117) is a small-molecule drug developed by Faeth Therapeutics. Its target is PIK3CA / PI3K-alpha. ClinicalTrials.gov describes the intervention as: Serabelisib is a selective, small molecule inhibitor of PI3Kα. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer and endometrial cancer. The largest, NCT06463028, plans to enrol 40 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at PIK3CA / PI3K-alpha, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to PIK3CA / PI3K-alpha.
1.Serabelisib slips into a pocket on PIK3CA / PI3K-alpha.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Serabelisib" OR ABSTRACT:"Serabelisib" OR TITLE:"FTH-001" OR ABSTRACT:"FTH-001" OR TITLE:"MLN1117" OR ABSTRACT:"MLN1117") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Serabelisib, not a curated reading list.
Shares Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer, Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial , Takeda, Endometrial cancer and the tag pipeline.
Shares Celcuity, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Celcuity and the tag pipeline.
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endometrial cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.